



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

December 17, 2004

Docket No. 03002971
Control No. 136100

License No. 37-00897-01

Joseph Cassidy
Regional Director of Imaging Services
Mercy Hospital
25 Church Street
Wilkes-Barre, PA 18765

SUBJECT: MERCY HOSPITAL, ISSUANCE OF LICENSE AMENDMENT, CONTROL NO.
136100

Dear Mr. Cassidy:

This refers to your license amendment request. Enclosed with this letter is the amended license. The fourth floor Nuclear Medicine Department may be released for unrestricted use.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Please note that on October 25, 2004, the NRC suspended public access to ADAMS, and initiated an additional security review of publicly available documents to ensure that potentially sensitive information is removed from the ADAMS database accessible through the NRC's web site. Interested members of the public may obtain copies of the referenced documents for review and/or copying by contacting the NRC Public Document Room pending resumption of public access to ADAMS. The NRC Public Document Room is located at NRC Headquarters in Rockville, MD, and can be contacted at 800-397-4209 or 301-415-4737 or pdr@nrc.gov.

Thank you for your cooperation.

Sincerely,

Original signed by Tara L. Weidner

Tara L. Weidner
Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 35

J. Cassidy
Mercy Hospital

2

cc:
Samuel L. Payne, Radiation Safety Officer

J. Cassidy
Mercy Hospital

3

DOCUMENT NAME: E:\Filenet\ML043560052.wpd

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI		DNMS/RI			
NAME	TWeidner /TLW/							
DATE	12-17-04							

OFFICIAL RECORD COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Mercy Hospital</p> <p>2. 25 Church Street Wilkes-Barre, Pennsylvania 18765</p>	<p>In accordance with the letter dated December 3, 2004,</p> <p>3. License number 37-00897-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date February 29, 2012</p> <p>5. Docket No. 030-02971 Reference No.</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Iodine 131 permitted by 10 CFR 35.300</p> <p>D. Palladium 103 permitted by 10 CFR 35.400</p> <p>E. Iodine 125 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources</p> <p>E. Sealed sources</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 300 millicuries</p> <p>D. 300 millicuries</p> <p>E. 500 millicuries</p>
<p>9. Authorized use:</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any sodium iodide iodine-131 imaging and localization study or therapy procedure permitted by 35.300, except thyroid carcinoma</p> <p>D. and E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</p>		

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-00897-01Docket or Reference Number
030-02971

Amendment No. 35

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 25 Church Street, Wilkes-Barre, Pennsylvania.
11. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

Champak M. Dedhia, M.D.

35.100; 35.200

Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

James Frangos, M.D.

35.100; 35.200

Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

Paul Leiman, M.D.

35.100; 35.200

Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

James Sundheim, M.D.

35.100; 35.200

Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

Joseph Rienzi, M.D.

35.100; 35.200

Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

Christopher N. Hobbie, M.D.

35.100; 35.200

Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-00897-01Docket or Reference Number
030-02971

Amendment No. 35

Authorized UsersMaterial and Use

Scott Alan Sauerwine, M.D.

35.100; 35.200

Douglas P. Cutillo, M.D.

35.100; 35.200

John Patrick Iannone, M.D.

35.100; 35.200

Robert A. Rostock, M.D.

Palladium 103 and Iodine 125 for procedures
permitted by 10 CFR 35.400

Farook K. Shroff, M.D.

35.200

Mallikarjun B. Udoshi, M.D.

35.200


12. The Radiation Safety Officer for this license is Samuel L. Payne, M.S.
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-00897-01Docket or Reference Number
030-02971

Amendment No. 35

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated August 30, 2001, except the Quality Management Program (ML012480192)
- B. Letter dated January 21, 2002 (ML020420152)
- C. Letter dated June 15, 2004 (ML041730049)
- D. Letter dated December 3, 2004 (ML043480309)



For the U.S. Nuclear Regulatory Commission

Original signed by Tara L. WeidnerDate December 17, 2004
bbbbbbbbbbbbbbbbbbbbbbbbbbBy _____
Tara L. Weidner
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406